Key result
Acute administration of verapamil in patients with hypertrophic cardiomyopathy significantly increased ventricular global peak filling rate from 283 to 325 %/EDV/s and improved contraction delay.
Why the study?
Does verapamil improve left ventricular function and contraction delay in patients with hypertrophic cardiomyopathy?
Population
11 patients with hypertrophic cardiomyopathy
Comparison
Verapamil vs Control period
Design
Case_series
Follow-up
2 weeks
Authors
Loading...
Does not support routine verapamil use in HCM; leaves open diastolic benefits for prospective trials.
Observational (n=11)
Does verapamil improve left ventricular function and contraction delay in patients with hypertrophic cardiomyopathy?
Absolute Event Rate: 325% vs 283%
Verapamil improves left ventricular contraction delay and peak filling rate in patients with hypertrophic cardiomyopathy without altering global systolic function.
Maul et al. (1988) conducted an observational in Hypertrophic cardiomyopathy (n=11). Verapamil vs. Baseline (off therapy) was evaluated on Ventricular global peak filling rate (%/EDV/s). Acute administration of verapamil in patients with hypertrophic cardiomyopathy significantly increased ventricular global peak filling rate from 283 to 325 %/EDV/s and improved contraction delay.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: